$SPR

$JD $SPCE $BA $SPR $SWN

Upgrades 12/7: $ABEV $ABG $AEGN $AZN $BA $BXG $CFB $COF $FITB $HAL $KL $LIN $LUV $LW $LYFT $PKG $RF $SPR $VOD $ZION

$SPR 35C Dec

Upgrades 11/10: $AINV $AVTR $AXP $BCS $BIIB $BKI $BYND $CAKE $CB $CHEF $CLB $CLH $CTVA $DDD $ESPR $ESS $HEP $ICPT $INO $KBH $LCUT $LEVI $MAXN $MCS $NNI $PDSB $PFGC $PZZA $RTX $SAN $SPR $SQ $SYY $TREE $USFD $VTR $W $WELL

Upgrades 11/4: $ADTN $AM $AMD $AMZN $BIDU $FMS $SPR $SYRS $SYY $TER $VC

(ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

SWEEP DETECTED: >>1072 $SPR Dec20 32.5 Calls trade $0.75 (FT Theo=0.65) ASKSIDE [MULTI] 11:06:51 IV=101.7% +7.1 OPENING Vol=1072, OI=377